



ANNUAL GENERAL MEETING **2010**



FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements regarding the company's business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing the company's goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising products that can be proven to be safe and effective for use as products in public health, pest management and for human and animal health therapeutics, and in the endeavor of building a business around such products and services. Actual results could differ materially from those discussed in this presentation. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the BioProspect Limited Annual Report for the year ended June 30, 2010, copies of which are available from the company or at www.bioprospect.com.



**2010 - A YEAR
OF SIGNIFICANT
PROGRESS AS WE
PUSH TOWARD
COMMERCIALISATION**



AGRI PRO™



termilone®

REGEN™

Qcide®



AGRIPRO™ 2010

- Commercialisation strategy formulated for AGRIPRO® products
- Initial focus on equine market; regulatory pathway in companion animals
- Market opportunities evaluated in Australia, New Zealand, UAE, USA, Europe
- Deed of Settlement agreed with Solagran as formal conclusion of Development Agreement
- Terms Sheet signed with supplier of Coniferous Chlorophyll-Carotene Paste (CC-CP) ex-Russia
- Agreed project with NZ based subsidiary of global supplier of products to the dairy industry; to develop and distribute AGRIPRO® products



AGRIPRO™ 2010

- AGRIPRO® & GI-GUARD® developed as brands for animal health & nutrition
- GI-GUARD® will be used for products for gastro-intestinal care.



- AGRIPRO® trademark registered/passed examination in Australia, New Zealand, Europe, USA, Hong Kong, Singapore
- GI-GUARD® trademark registered in Australia & now being registered as per AGRIPRO®



AGRIPRO™

2010

- Successfully completed major equine safety trials
- GI-GUARD® Oral Paste for gastro-intestinal care
- AGRIPRO® Topical Gel for wounds & skin conditions
- Conducted to international protocols with ethics approval & quality assurance controls
- Essential requirement to support registration





AGRI PRO™ 2010

- APVMA registration under Category 2 for Veterinary Herbal Remedies
 - Part 2: Product Chemistry
 - Part 8: Efficacy/Safety
 - Part 3: Toxicology NOT required
- Timeframe 10-12 months
- Submitted application to APVMA for registration of GI-GUARD® Oral Paste for horses
- Active constituent & Product Chemistry (Part 2)
- Efficacy & Safety (Part 8) yet to be submitted





AGRIPRO™ 2011

- Conclude arrangements for commercial supply of CC-CP
- Complete branding strategy for GI-GUARD® & AGRIPRO® as registered trademarks in key target markets
- Complete pilot efficacy study with GI-GUARD® Oral Paste for treatment of Equine Gastric Ulcer Syndrome (EGUS)
- Submit efficacy & safety data package for GI-GUARD® Oral Paste to APVMA with aim to obtain approval and sales in Q4 2011





AGRIPRO™ 2011

- Formulation development for range of CC-CP based products including gel, salve, pellets, block products.





AGRIPRO™ 2011

- Enter into Market Development agreement with NZ division of global company to develop & commercialise AGRIPRO® products with applications focused in the dairy segment.





AGRIPRO™ 2011

- Market development & evaluation of GI-GUARD® & AGRIPRO® products in equine & other segments
- Distribution and/or licensing arrangements with local and international commercial collaborators





2010

- Completed laboratory studies to establish minimum effective concentrations (MEC) of TERMILONE® vs. key termite species & determine residual activity under laboratory conditions
- MEC's lie between 5000 & 7500 ppm; 10,000 ppm application did not provide 6 months control in soil in lab

Fig 1. Set-up of horizontal assay tubes (25 mm diam. x 250 mm).





2010

- Field testing of TERMILONE[®] 80EC in collaboration with Ensystem; confirmed 10,000ppm did not provide 6 months activity in the field
- Undertook economic evaluation & decision made to suspend development in termite control/timber treatment





termilone[®] 2011

- Complete evaluation of potential for Eremophilone oil as an essential oil/fragrance
- Complete patent approvals in Japan & USA with minimal additional investment
- Determine commercial interest in Eremophilone oil data package





Qcide[®] 2010

- Tasmanone natural insecticide with proven activity against a range of insect species including flies, mosquitoes, cockroaches, ectoparasites and crop pests
- Patents for insect control granted in Australia, New Zealand, Japan, USA and Europe
- IP Assignment Deed signed with Bio-Gene Technology to commercialise via grow out & production program, evaluation and licensing and/or sale
- Fee installments & royalties payable to BPO & UWS



REGEN™

2010

- Concluded acquisition of Re-Gen Wellness Products & entered natural health & skin care markets
- Novel products developed under the REGEN® & Demure® brands
- ARTG listing for REGEN® therapeutic products





REGEN™

2010

- Re-launch of REGEN® products
- New product launch: REGEN® Pain Relief Spray

REGEN™

Topical Relief

PAIN RELIEF SPRAY

TRADITIONAL TWEED AND FOR JOINT AND MUSCULAR ACHES & PAINS

AUST. T 1800 988 357 NAT 1800 988 357

REGEN™

Distributed by:
The One Healthcare Products Pty Ltd
202 Parklands Rd, St Helens
QLD 4050 Australia
T: 1800 988 357
MADE IN AUSTRALIA
www.regen.com.au

REGEN™

Emu Oil
Food Capsules

REGEN™

DIETARY SUPPLEMENT
(All natural product)

Distributed by:
The One Healthcare Products Pty Ltd
202 Parklands Rd, St Helens
QLD 4050 Australia
T: 1800 988 357
MADE IN AUSTRALIA
www.regen.com.au



REGENTM

2011

- Grow sales of newly expanded REGEN[®] range of therapeutic products
- Consolidate IP associated with both REGEN[®] & Demure[®] ranges via formulation technology & branding
- Seek commercial opportunities for Demure[®] range of skin care products





THE WAY FORWARD 2011



**COMMERCIALISE PRODUCTS & IP
ACTIVELY **SEEK** FOCUSED
**ACQUISITION TARGETS, TO GROW
THE DEPTH AND SCALE OF THE
BPO BUSINESS****



ANNUAL GENERAL MEETING **2010**